JPS58180487A - Antibiotic dc-81 and its preparation - Google Patents
Antibiotic dc-81 and its preparationInfo
- Publication number
- JPS58180487A JPS58180487A JP6363082A JP6363082A JPS58180487A JP S58180487 A JPS58180487 A JP S58180487A JP 6363082 A JP6363082 A JP 6363082A JP 6363082 A JP6363082 A JP 6363082A JP S58180487 A JPS58180487 A JP S58180487A
- Authority
- JP
- Japan
- Prior art keywords
- culture
- medium
- color
- hyphae
- streptomyces
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
【発明の詳細な説明】
本発明は新規抗生物質およびその製造法に関し、とくに
本発明者によってDo−81と帛名された新規抗生物質
およびその製造法に関する。DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a novel antibiotic and a method for producing the same, and particularly to a novel antibiotic named Do-81 by the present inventor and a method for producing the same.
本発明は、ストレプトマイセス槙に属するある種の微生
物が、新規抗生物質T) O−81を生産するという知
見に基いている。The present invention is based on the finding that certain microorganisms belonging to the Streptomyces genus produce the novel antibiotic T) O-81.
本発明の目的は新規で有用な物質を提供することにある
。An object of the present invention is to provide new and useful substances.
本発明による新規物質D C−81は、次の平面構造式
によって特定される新規化合物であることを特徴として
いる。The novel substance D C-81 according to the present invention is characterized by being a novel compound specified by the following planar structural formula.
DO−81は後述のように、ある種の菌に抗菌活性を示
すので、それらの菌を原因菌とする感染症に対して治療
効果を有するものと期待される。またDC−81は抗腫
瘍作用を示すことを醪めた。As will be described later, since DO-81 exhibits antibacterial activity against certain types of bacteria, it is expected to have a therapeutic effect on infectious diseases caused by these types of bacteria. In addition, DC-81 was found to exhibit antitumor effects.
本物質はいわゆる1、4−ベンゾジアゼピン誘導体に属
し、鎮痛、鎮静、鎮痙剤としての用途の可能性もある。This substance belongs to the so-called 1,4-benzodiazepine derivatives, and may also be used as an analgesic, sedative, and antispasmodic agent.
本発明によるDO−81物質の理化学的性質および生物
j学的性質は次の通りである。The physicochemical and biological properties of the DO-81 substance according to the present invention are as follows.
■、理化学的性質
(リ 融点= 98〜105℃
(2) 分−1it: 246(マススペクトル法
)(3)分子式: ”s 8H14”3N2(4)紫
外部吸収スペクトル(メタノール中):224.236
,260(ah)、316(nm )
(5)赤外部吸収スペクトル(KBr錠剤法):第1図
に示す。(2) Physical and chemical properties (melting point = 98-105°C (2) min-1it: 246 (mass spectrometry) (3) Molecular formula: "s 8H14" 3N2 (4) Ultraviolet absorption spectrum (in methanol): 224. 236
, 260 (ah), 316 (nm) (5) Infrared absorption spectrum (KBr tablet method): Shown in FIG.
(5)PMR,スペクトル(重水素置換クロロホルム中
、TM8基進)(ppm):
1.8〜2.33 (4H)、3.3〜3.8(3H)
、3.84(3H)、6.89(IH)。(5) PMR, spectrum (TM8 group in deuterium-substituted chloroform) (ppm): 1.8-2.33 (4H), 3.3-3.8 (3H)
, 3.84 (3H), 6.89 (IH).
7.48(IH)、7.63(IH)
(7)OMRスペクトル(重水素置換クロロホルム中、
TMS基準):
24.2.29.5.46.7.53.7. F16.
0゜111.4,113.1,119.4,140.8
゜146.2,149.2,162.5,164.9(
8) 比旋光度;〔α:]’j=+135° (00
,2゜メタノール)
(9) 溶解性ニジメチルスルホキシド、メタノール
、クロロホルム、アセトンにヨく
とける。酢酸エチル、水に可溶、エチ
ルエーテル、n−ヘキサンにはほとん
どとけない。7.48 (IH), 7.63 (IH) (7) OMR spectrum (in deuterated chloroform,
TMS Standard): 24.2.29.5.46.7.53.7. F16.
0°111.4, 113.1, 119.4, 140.8
゜146.2, 149.2, 162.5, 164.9 (
8) Specific rotation; [α:]'j=+135° (00
, 2°methanol) (9) Soluble in dimethyl sulfoxide, methanol, chloroform, and acetone. Soluble in ethyl acetate and water, almost insoluble in ethyl ether and n-hexane.
(10) Rf値:薄層クロマトグラフィー〔シリカ
ゲル(商品名Klese1gel 60 Art。(10) Rf value: Thin layer chromatography [Silica gel (trade name: Kleselgel 60 Art.
5721、E、 Merck、西独)を用い・室温で3
時間展開〕でのRf値は第1
表の通りである。5721, E, Merck, West Germany) at room temperature.
The Rf values in [time evolution] are shown in Table 1.
第 1 表
展 開 剤 R,fクロロ
ホルム・アセトン(33:67v/V) 0.3
8りooホルム・メタy−ル(9:Jv/v)
0.290.05N N)(40H飽和酢酸エチル
0.12トルエン・エタノール・アンモニア水
0 、27(40:10:0.1 v/v)
(1)〜(9)
上吠ガ甲化学的件質から本発明化合物は次の平面構造式
を有すると決定された。Table 1 Developing agent R, f Chloroform/acetone (33:67v/V) 0.3
8rioo form metayr (9: Jv/v)
0.290.05N N) (40H saturated ethyl acetate
0.12 Toluene/Ethanol/Aqueous ammonia 0,27 (40:10:0.1 v/v) (1) to (9) From the chemical properties of the shell shell, the compound of the present invention has the following planar structural formula. It was determined that the
■、生物学的性質 (1)抗菌活性 抗菌活性(寒天稀釈法、pH7,0)を第2表に示す。■, biological properties (1) Antibacterial activity The antibacterial activity (agar dilution method, pH 7.0) is shown in Table 2.
次表の通り、D C’、 −81物質は抗菌活性を有し
、抗菌剤あるいは消毒剤としての用途が期待できる。As shown in the table below, substance D C', -81 has antibacterial activity and can be expected to be used as an antibacterial agent or disinfectant.
第 2 表
試験菌者 MIO(μIIAnlり
スタフィロコッカス・アウレウス 50ATO
O6538P
バチルス拳ズブチリス 50107
07
エシェリキア・コリ 200TO
O26
サルモネラΦタイホサ 50ATO
O9992
シゲラ・ゾネイ 50A
TOO9290
(2)急性前件
和性宿性(LD5o)は、マウスへの腹腔内投与の場合
42Tn9/に9である。Table 2 Test bacteria MIO (μIIAnl Staphylococcus aureus 50ATO
O6538P Bacillus fistula 50107
07 Escherichia coli 200TO
O26 Salmonella Φ Taihosa 50ATO
O9992 Shigella zonei 50A
TOO9290 (2) Acute antecedent toxicity (LD5o) is 42Tn9/9 when administered intraperitoneally to mice.
(3)抗腫瘍活性
リンホサイテイツク・リュケミアP−
388腫瘍に対する効果
体重約229の0DFl雄マウス1群5匹に、リンホサ
イテイツクeリュケばア(Lymphocytlc l
eukemia ) P −388腫瘍細胞I X 1
06 個を腹腔内移植した。(3) Antitumor activity Effect on Lymphocyts lykemia P-388 tumors Groups of 5 0DF1 male mice weighing approximately 229 were given Lymphocyts lykemia P-388 tumor.
eukemia) P-388 tumor cells IX1
06 cells were implanted intraperitoneally.
移植後24時間目にDO−81物質の生理食塩水溶液o
、2mlを1回腹腔内に投与しまた。DO-81 substance in saline solution 24 hours after implantation
, 2 ml was administered intraperitoneally once.
比較例として、腫瘍細胞移植後24時間目にマイトマイ
シン0の生理食塩水溶液0.2mlを膀腔内投与した群
を設けた1、移植後の平均生存日数およびT/C(T:
試験例の平均生存日数、O:対照の平均生存日数)を第
3表に示す。As a comparative example, a group was established in which 0.2 ml of mitomycin 0 in physiological saline was administered intraveinally 24 hours after tumor cell transplantation.
The average survival days of the test examples (O: average survival days of the controls) are shown in Table 3.
第 3 表
本発明による抗生物質DC−81の製造法は、ストレプ
トマイセス属に属シ2、DC−8]を生産する能力を有
する微生物を培地に培養し2、DC−81を培養物中に
蓄積させ、この培養物がらDO−81を採取することに
よって得ることを特徴としている。Table 3 The method for producing the antibiotic DC-81 according to the present invention involves culturing in a medium a microorganism capable of producing genus Streptomyces [2, DC-8], and culturing DC-81 in the culture. DO-81 is collected from this culture.
本発明において使用する微生物はストレプトマイセス属
に属し、DC−81を生産する能力を有する微生物であ
ればいずれの微生物も用いることができるが、好適な菌
の例は本発明者が静岡系三島市内の土壌から分離した菌
株1)O−81株(微ニゲ[菌寄第6502号)である
。本菌株の菌学的性質は次の通りである。The microorganism used in the present invention belongs to the genus Streptomyces, and any microorganism can be used as long as it has the ability to produce DC-81. Bacterial strain 1) isolated from soil in the city is strain O-81 (Micronige [Bacteria No. 6502]). The mycological properties of this strain are as follows.
■、形態的性質
本菌株は、種々の天然および合成培地で良好もしくは普
通の生育を示し、その水生菌糸の色は一般に薄黄色ない
し茶色であるが、とくにグリセロール・アスパラギン寒
天培地、卵・アルダばン寒天培地もしくはブドウ糖・酵
母エキス寒天培地では赤色を帯びる。この(7)
色素はpHインディケータ−ではない。気中菌糸の着生
は、スターチ・寒天培地では良好であるが、全般的には
普通の着生を示し、その色調は白色ないし灰色である。■ Morphological properties This strain shows good or normal growth on various natural and synthetic media, and the color of its aquatic hyphae is generally pale yellow to brown, but it is especially suitable for glycerol-asparagine agar, egg, and alda barium. When used on agar medium or glucose/yeast extract agar medium, it becomes reddish. This dye (7) is not a pH indicator. Aerial hyphae colonization is good on starch/agar media, but generally shows normal colonization and is white to gray in color.
胞子は、伸長した気中菌糸から単純分枝した胞子柄に1
0個以上のらぜん状連(fil(spiralg)
として着生する。胞子の形態は楕円ないし卵形で大きさ
は1.0〜1.1μ×0.4〜0.6μであり、電子顕
微鏡観察による胞子表面は平滑(smooth)ないし
粗面(warty) で鞭毛は認められない。Spores are 1 spore on a sporophyte that is simply branched from an elongated aerial hyphae.
Zero or more spirals (fil(spiralg)
It grows as an epiphyte. The shape of the spore is elliptical or oval, and the size is 1.0-1.1μ x 0.4-0.6μ.The spore surface is smooth or warty according to electron microscopy, and the flagellum is unacceptable.
また胞子のりも見い出されない。Also, no spores were found.
■、各種培地上での生育状態
各種培地上で28℃で2週間培養したときの生育および
色の特徴を下記に示す。色の表示は0olor Har
mony Manual (0ontaln@rOor
poration of America )による色
の分類による。可溶性色素は、使用した培地のいずれに
も検出されない。(2) Growth status on various media The characteristics of growth and color when cultured on various media at 28° C. for 2 weeks are shown below. Color display is 0olor Har
mony Manual (0ontaln@rOor
According to the color classification according to the United Nations Corporation of America). No soluble dye is detected in any of the media used.
(1) シュクロース・硝酸塩寒天培地生育: 良
好、平坦
(8)
水生菌糸の表面、裏面の色:フレッシュ・ピンク(4c
a)ないしフレック
ュφピンク(5ca )
安中菌糸:普通、白色(a)
(2) グルコース・アスパラギン寒天培地生育:
貧弱、隆起状
水生菌糸の表面、裏面の色ニライト・アイポリ−(2c
a)ないしフレック
ュ・ピンク(5ca )
気中菌糸:なし
く3)グリセロール・アスパラギン寒天培地生育:
普通、平坦
水生菌糸の表面、裏面の色:チェスナツツ・ブラウン(
4nl)
気中菌糸:貧弱、白色(&)
(4)スターチ・無機塩寒天培地
生育: 良好、隆起状
水生菌糸の表面、裏面の色:マーブル(41θ)ないし
ライト・ブラウン(4ng)
気中菌糸:豊富、白色(a)ない1−フレツシュ9ピン
ク(4ca)
(5)卵・アルブミン寒天培地
生育: 貧弱、平坦
基中菌糸の表面、裏面の色:ダーク・ラッカー−レッド
(6pe )
又中菌糸:貧弱、白色(a)
(6)栄養寒天培地
生育: W通、平坦
基中菌糸の表面、裏面の色ニライト・イエロー(13/
2c a )
気中菌糸:普通、ピンク・チント(7ba)(7)酵母
エキス・麦芽エキス寒天培地生*: 普通、隆起状
基中菌糸の表面、裏面の色ニライト・ウイート(2・a
)
気中菌糸:普通、バール・シェル・チント(3ba)
(8)オートば−ル轢天培地
生育: 良好、隆起状
基中菌糸の表面、裏面の色:バンブー(2ge)気中菌
糸:普通、白色(a)ないしアイポリ−・テント(2e
b)
(9) グルコース・酵母エキス寒天培地生育:
良好2粒状
基中菌糸の表面、裏面の色ニライト・アイポリ−(2c
a)ないしディープ・
レッド・ブラウン(6/2pl)
気中菌糸:普通、白色(a)ないし灰色(5fe)
(10)ベネット氏寒天培地
生育: 普通、隆起状
基中菌糸の表面、裏面の色:バンブー(2gc)気中菌
糸:普通、サンド(3ab)
(11)エマーソン氏寒天培地
生育: 普通2粒状
基中菌糸の表面、裏面の色:バール・ピンク(2gc
)
気中菌糸:普通、オーキッド・チン)(10ba)
(12)ヒツキー・トレスナー氏寒天培地(11)
生育: 良好、隆起状
基中菌糸の表面、裏面の色ニライト・アイポリ−(2c
m)
気中菌糸:普通、パール拳シェル・チント(3ba)
(13)ペプトン・酵母エキス・鉄寒天培地生育:
普通、隆起状
基中菌糸の表面、裏面の色二バール・ピンク(3ca)
気中菌糸:普通、白色(&)
(14)チロシン寒天培地
生育: 普通、隆起状
基中菌糸の表面、裏面の色:フレッシュ・ピンク(5c
m)ないしバーガン
ディ(7pl)
気中菌糸:普通、フレッシュ会ピンク(4cm)<15
) グリセロール・リンゴ酸カルシウム寒天培地
生育: 普通、平坦
基中菌糸の表面、表面の色:オールド・ワ(]2)
イン(7/!ng)
気中菌糸二貧弱、白色(a)
■、生理的性質
(1)炭素源の資化性(プリドハム・ゴドリーブ寒天培
地上):D−グルコース、L−7ラビノース、D−キシ
ロース、l−イノシトール、D−マンニトール、D−フ
ラクトース、L−ラムノース、シュクロース、D−ラフ
ィノースを資化する。(1) Growth on sucrose/nitrate agar medium: Good, flat (8) Color of front and back surfaces of aquatic mycelia: Fresh pink (4c)
a) or fleck φ pink (5ca) Annaka mycelium: normal, white (a) (2) Growth on glucose-asparagine agar medium:
Color of the surface and back of poor, raised aquatic hyphae Nirite Ipoly (2c
a) Or fleck pink (5ca) Aerial mycelium: None 3) Growth on glycerol-asparagine agar medium:
Normally, the color of the front and back sides of flat aquatic mycelium: chestnut brown (
4nl) Aerial hyphae: Poor, white (&) (4) Growth on starch/inorganic salt agar medium: Good, color of the surface and back of raised aquatic hyphae: Marble (41θ) or light brown (4ng) Aerial hyphae : Abundant, White (a) No 1-Fresh 9 Pink (4ca) (5) Growth on egg/albumin agar medium: Poor, flat base Color of surface and back of hyphae: Dark lacquer-red (6pe) Also medium hyphae : Poor, white (a) (6) Nutrient agar medium growth: W-through, flat base medium hyphae color nirite yellow (13/
2c a) Aerial hyphae: Normal, pink tint (7ba) (7) Yeast extract/malt extract Agar medium raw *: Normal, color of the surface and back of the raised basal hyphae Nirite wheat (2.a)
) Aerial hyphae: Normal, Burl shell tint (3ba) (8) Autobar terrarium growth: Good, color of surface and underside of raised base hyphae: Bamboo (2ge) Aerial hyphae: Normal , white (a) or ipoly tent (2e
b) (9) Growth on glucose/yeast extract agar medium:
Good color of the surface and back of the 2 granular hyphae Nilite/Ipoly (2c
a) or deep red brown (6/2 pl) Aerial hyphae: Normal, white (a) or gray (5fe) (10) Growth on Bennett's agar medium: Normal, color of the surface and back of the hyphae in the raised base : Bamboo (2gc) Aerial mycelium: Normal, Sand (3ab) (11) Emerson's agar medium Growth: Normal 2 granular base Medium color of surface and back side of mycelium: Burl pink (2gc)
) Aerial hyphae: Ordinary, Orchid Chin) (10ba) (12) Hitzky-Tressner's agar medium (11) Growth: Good, color of the surface and back of the raised basal hyphae Nirite ipoly- (2c)
m) Aerial mycelium: normal, pearl fist shell tint (3ba) (13) Peptone/yeast extract/iron agar medium growth:
Normally, the color of the front and back sides of the hyphae in the raised base is bivar pink (3ca) Aerial hyphae: Normal, white (&) (14) Growth on tyrosine agar medium: Normal, the color of the front and back sides of the hyphae in the raised base Color: Fresh pink (5c
m) or burgundy (7 pl) Aerial mycelium: normal, fresh pink (4 cm) <15
) Growth on glycerol/calcium malate agar medium: normal, flat base, surface of medium hyphae, surface color: old wa (]2) in (7/!ng) aerial hyphae poor, white (a) ■, physiological Properties (1) Assimilation of carbon sources (on Pridham-Godelive agar medium): D-glucose, L-7 rabinose, D-xylose, l-inositol, D-mannitol, D-fructose, L-rhamnose, Assimilates claus and D-raffinose.
(2)ゲラチンの液化作用: なし。(2) Liquefaction effect of gelatin: None.
(3)ミルクに対する作用: 凝固も液化もしない。(3) Effect on milk: Neither coagulate nor liquefy.
(4)スターチの加水分解作用:あり。(4) Starch hydrolysis effect: Yes.
(5)生育温度範囲: 20〜40’C(6)
メラニン様色素の生成: なし。(5) Growth temperature range: 20-40'C (6)
Production of melanin-like pigment: None.
ただし、(2)ゲラチンの液化作用は20℃で3週間後
、(3)バルクに対する作用については28℃で3週間
後、(5)生育温度範囲は5日後、その他については2
8℃で2週間後の観察結果である。However, (2) the liquefaction effect of gelatin occurs after 3 weeks at 20℃, (3) the effect on bulk gelatin after 3 weeks at 28℃, (5) the growth temperature range after 5 days, and the other conditions
These are the observation results after 2 weeks at 8°C.
■、細胞壁組成
細胞壁構成アミノ酸の一つであるジアミノピメリン酸を
分析した結果、LL−2,6−ジアミノピメリン酸が検
出された。(2) Cell wall composition As a result of analyzing diaminopimelic acid, which is one of the amino acids constituting the cell wall, LL-2,6-diaminopimelic acid was detected.
上記の菌学的性質において、気中菌糸を形成し、単純分
枝をなし、その先端に長い胞子鎖を形成し、さらに細胞
壁にL L−ジアミノピメリン酸を含むことから、本菌
株は放線菌目の中でストレプトマイセス属に分類される
。In terms of the above-mentioned mycological properties, this strain forms aerial hyphae, has simple branches, forms long spore chains at the tips, and contains L-diaminopimelic acid in its cell wall, so this strain belongs to the order Actinobacteria. It is classified as a member of the genus Streptomyces.
■1種の同定
本菌株は胞子鎖がらせん状をなし、スパイラル(Bpl
ral)セクションに属し、胞子表面は平滑(amoo
th)もしくは粗面(warty) である。各種寒
天培地上での気中菌糸の色は、おおむね白色で、薄黄も
しくはピンクを帯びた灰色の場合もある。しかし、グリ
ーンやブルー系の色は示さない。基生菌糸の色は、クリ
ームからオレンジもしくはブラウン系の色で、とくにグ
リセロール・リンゴ酸カルシウム寒天培地および卵・ア
ルブミン寒天培地で(]5)
は赤色を示すのが特徴的である。いずれの場合も色素は
pHインディケータ−ではない。■Identification of one species In this strain, the spore chain has a spiral shape (Bpl
ral), and the spore surface is smooth (amoo).
th) or a rough surface (warty). The color of aerial mycelia on various agar media is generally white, but may also be pale yellow or pinkish gray. However, it does not exhibit green or blue colors. The color of the basal hyphae ranges from cream to orange or brown, and is particularly characteristically red on glycerol/calcium malate agar and egg/albumin agar (]5). In either case the dye is not a pH indicator.
甘た、可溶性色素およびメラニン様色素の産生は見られ
ない。炭素源として、L−アラビノース、D−キシロー
ス、l−イノシトール、D−マンニトール、L−ラムノ
ース、D−ラフィノースなど広い糖資化能を有する。Production of sweet, soluble pigments and melanin-like pigments is absent. As a carbon source, it has a wide range of sugar assimilation abilities such as L-arabinose, D-xylose, l-inositol, D-mannitol, L-rhamnose, and D-raffinose.
本菌株の類似株を、細菌学名承認リスト(Int、 J
、 System、 Bacterlol、 30巻
。Similar strains of this strain were listed on the Approved List of Bacterial Scientific Names (Int, J
, System, Bacterol, 30 volumes.
225頁、1980年)において承認されている既知菌
株の中から探索した結果、Int。Int.
J、System、 Bacterlol、 18巻
、69頁。J, System, Bacterol, vol. 18, p. 69.
279頁、1968年、19巻、391頁。279 pages, 1968, vol. 19, p. 391.
1969年、22巻、265頁、1972年から、次の
6菌種が近縁種として挙げられる。1969, Volume 22, Page 265, 1972, the following six bacterial species are listed as closely related species.
ストレプトマイセス・ロゼイスフレロティカス(Str
eptomyces roselsclerotlcu
m)sストレプトマイセス・スフレロチイアラス(8,
aclerotlalug ) 、ストレプトマイセス
・リバニー(S、 1lbanl )、ストレプトマ(
16)
イセス拳オカーセイスクレオテイカス(S。Streptomyces roseis fleuroticus (Str.
eptomyces roselsclerotlcu
m) Streptomyces soufflelothiaras (8,
aclerotlalug), Streptomyces livanii (S, 1lbanl), Streptomyces (
16) Ises Fist Okaseiscleoteikas (S.
ochraceiacleoticus )Xストレプ
トマイセス・フロカルス(S、 flocculus)
およびストレプトマイセス・ビナセウスードラブス(S
、 vinaoeus−drappus ) nこれら
の菌株のうち、ストレプトマイセス争ロゼイスクレロテ
イカスおよびストレプトマイセス・スフレロチイアラス
、ストレフトマイセス・オカーセイスクレオテイカスは
いずれも菌核を形成するタイプの菌種であるが、本菌株
では菌核の形成は見られない。しかし、菌核を形成する
菌種においても、気中菌糸を比較的よく着生する場合は
菌核がMられないことが知られている。従って、気中菌
糸が豊富に形成される本菌株の同定にあたっては、菌核
の有無を考慮から除外した。ochraceiacleoticus)X Streptomyces flocculus (S, flocculus)
and Streptomyces binaceus sutrabus (S
, vinaoeus-drappus) n Among these strains, Streptomyces roseis scleroteicus, Streptomyces soufflerochiaras, and Streptomyces ocaseis scleroteicus are all types that form sclerotia. However, the formation of sclerotia is not observed in this strain. However, it is known that even in bacterial species that form sclerotia, sclerotia do not become M if they are relatively well attached to aerial mycelia. Therefore, the presence or absence of sclerotia was excluded from consideration when identifying this strain, which forms abundant aerial hyphae.
これら6株を文献上でさらに詳細に本菌株と比較したと
ころ、気中菌糸と基生菌糸の色調において相違が見られ
た。When these six strains were compared with the present strain in more detail in the literature, differences were found in the color tone of aerial hyphae and basal hyphae.
+i r+IWi糸については、ストレプトマイセス・
ロゼイスフレロティカスとストレプトマイセス・スフレ
ロチイアラスの両法は本枕と類似しているが、他の4株
では、本枕と比較してブラウンの色調が濃蘭であつ友。For +i r+IWi yarn, Streptomyces
Both Roseis fleuroticus and Streptomyces soufflerotiaras are similar to Honmakura, but the other four strains have a darker brown tone compared to Honmakura.
基生菌糸においては、6株ともイエローもしくはブラウ
ン系の色を示すが、本枕の特徴とみなせるレッド系の色
を含むものは、ストレフトマイセス・ロゼイスフレロテ
ィカスのみであった。In terms of basal hyphae, all six strains exhibited a yellow or brown color, but only Strephtomyces roseis fleuroticus had a red color, which can be considered a characteristic of this pillow.
従って、オートミール寒天培地での基生菌糸の色−が濃
い点を除けば、ストレプトマイセス・ロゼイスフレロテ
ィカスが本菌株と比較的よく一致していると判断した。Therefore, it was determined that Streptomyces roseis fleuroticus was relatively similar to this strain, except for the dark color of the basal hyphae on the oatmeal agar medium.
よって本菌株をストレプトマイセス・ロゼイスフレロテ
ィカスD O−81(Strepto−myces r
oseisclerotlcus Do −81)と命
名し、工業技術院微生物工業技術研究所に微工研菌寄第
6502号として寄託した。Therefore, this strain was transformed into Streptomyces roseis fleuroticus DO-81 (Strepto-myces r.
oseisclerotlcus Do-81), and was deposited with the Institute of Microbiology, Agency of Industrial Science and Technology as Microbiological Laboratory Deposit No. 6502.
次に培養法について述べる。本発明の培養法は通算の放
線菌の培養と同様である。すなわち、培地の炭禦源とし
ては、たとえばブドウ粘、殿粉、デキストリン、マンノ
ース、フラクトース、シュクロース、ラクトース、糖蜜
が単独せたは組み合わせて用いられる。さらに、菌の資
化能によっては炭化水素、アルコール類、有機酸なども
用いられる。蟹素源としては、塩化アンモン、硫酸アン
モン、硝酸アンモン、硝酸ソーダ、尿素などの窒素合櫓
化合物、およびペプトン、肉エキス、酵母エキス、乾h
w母、コーン・スチープ・リカー、大豆粉、カザミノ酸
などのちく素含有天然物が単独またけ組み合わせて用い
られる。必要に応じて、食塩、塩化カリ、硫酸マクネシ
ウム、炭酸カルシウム、燐酸二水素カリウム、燐酸水素
二カリウム、k酸第−鉄、塩化カルシウム、硫酸マンガ
ン、硫酸亜鉛、硫酸銅などの無機塩類を加えてもよい。Next, we will discuss the culture method. The culture method of the present invention is similar to the culture of total actinomycetes. That is, as a charcoal source for the medium, for example, grape viscosity, starch, dextrin, mannose, fructose, sucrose, lactose, and molasses are used alone or in combination. Furthermore, depending on the assimilation ability of the bacteria, hydrocarbons, alcohols, organic acids, etc. may also be used. Crab sources include nitrogen compounds such as ammonium chloride, ammonium sulfate, ammonium nitrate, sodium nitrate, and urea, as well as peptone, meat extract, yeast extract, and dried
Chichrine-containing natural products such as milk, corn steep liquor, soybean flour, and casamino acids are used singly or in combination. If necessary, add inorganic salts such as common salt, potassium chloride, magnesium sulfate, calcium carbonate, potassium dihydrogen phosphate, dipotassium hydrogen phosphate, ferric chloride, calcium chloride, manganese sulfate, zinc sulfate, copper sulfate, etc. Good too.
さらに使用菌の生育″v′T)O−81の生産を促進す
る微振成分タトえばビタばンBl、ビオチンなどを適当
に添加することができる。Furthermore, vitabane Bl, biotin, etc., which promote the growth of the microorganism used and the production of O-81, may be appropriately added.
培養法としては、液体培養法、とくに深部攪10、とく
に6〜8が適当で、アンモニア水や炭酸アンモニア水な
どでpHを調節する。液体培養の場合、通常1日f、c
いし7日の培養で、著址の目的物質no−s iが培養
液中に生成蓄積される。培養物中の蓄積量が最大に達し
たときに培養を停止し、菌体をP別する。As a culture method, a liquid culture method, particularly deep agitation 10, especially 6 to 8, is suitable, and the pH is adjusted with aqueous ammonia, aqueous ammonia carbonate, or the like. In the case of liquid culture, usually 1 day f, c
After 7 days of culture, a significant amount of the target substance no-si was produced and accumulated in the culture solution. When the amount accumulated in the culture reaches the maximum, the culture is stopped and the bacterial cells are separated from P.
培養r液からのi) O−81物質の単離精製には、微
生物代謝生産物を、その培養液からJIP離するために
用いられる通常の分離・精製法を利用することができる
。たとえば、培養1液(たとえばp)16.0 )を活
性炭(和光紬薬)に通塔して活性成分を吸着させた後、
メタノール・ピリジン・アンモニア・水(86:3:1
:10v/ v )などを用いて活性炭から吸着された
物質を溶出する。沼出液を濃縮乾固し、pH7,0の適
当な緩衝液に溶解し、n−ブタノールなどの溶媒で抽出
する。抽出液を濃縮乾固し、アンモニア水飽和酢酸エチ
ルに溶解する。この溶液を予め同じ溶媒で懸濁後、カラ
ムに充填したシリカゲルを用いてクロマトグラフィーを
行なう。i) Isolation and purification of the O-81 substance from the culture solution can be performed using conventional separation and purification methods used to separate microbial metabolic products from the culture solution. For example, after passing a culture solution (for example, p 16.0) through activated carbon (Wako Tsumugi Co., Ltd.) to adsorb active ingredients,
Methanol/pyridine/ammonia/water (86:3:1
:10v/v) etc. to elute the adsorbed substance from the activated carbon. The solution is concentrated to dryness, dissolved in a suitable buffer solution having a pH of 7.0, and extracted with a solvent such as n-butanol. The extract was concentrated to dryness and dissolved in ethyl acetate saturated with aqueous ammonia. This solution is suspended in the same solvent in advance, and then chromatography is performed using silica gel packed in a column.
アンモニア水飽和酢酸エチルで溶出し、活性画分を濃縮
乾固し、少量のメタノールに溶解する。Elute with aqueous ammonia and saturated ethyl acetate, concentrate the active fraction to dryness, and dissolve in a small amount of methanol.
このメタノール溶液を、予めメタノールに懸濁した後カ
ラムに充填したセファデックスL H−20(Phar
macla Fine Chemicals Inc、
。This methanol solution was suspended in methanol in advance and then packed into a column using Sephadex L H-20 (Phar
macla Fine Chemicals Inc.
.
Sweden)のカラムに通塔し、DO−81の両分を
得る。これを酢酸エチルまたはクロロホルム・エチルエ
ーテル・石油エーテルの混合溶媒から結晶化させてDo
−81を得ることができる。(Sweden) column to obtain both portions of DO-81. This was crystallized from ethyl acetate or a mixed solvent of chloroform, ethyl ether, and petroleum ether.
-81 can be obtained.
実施例1
種菌としてストレプトマイセス・ロゼイスフレロティカ
スDo−81を用いた。Example 1 Streptomyces roseis fleuroticus Do-81 was used as a seed strain.
の
菌株を21容量の三角フラスコ中に種培地〔デキストリ
ン20 & / A’ r グルコース109/l、ペ
プトン1011/11.コーンφスチープ・リカー51
1/l、酵母エキス1g/)、 K)(2PO40−
5F / l 、N1gSO4・7H2C) 0.5
g/ l t Oaoo a[7/j!(pH7,2
)〕3oodに植菌し、30℃で48時間振とり(22
0r、p、m、)培養した。得られた培養液を301容
量のジャーファーメンタ−中の下記組成の発酵培地15
1に5チ(容量)の割合で移し、30℃で通気攪拌方式
(回転数25 Or、 p、 m6、通気i′15)7
m1n)により培養を行なった。In a 21-volume Erlenmeyer flask, a strain of the following was added to the seed medium [dextrin 20 &/A' r glucose 109/l, peptone 1011/11. Corn φ Steep Liquor 51
1/l, yeast extract 1g/), K) (2PO40-
5F/l, N1gSO4・7H2C) 0.5
g/ l t Oaoo a[7/j! (pH7,2
)] Inoculated into 3 ood and shaken at 30℃ for 48 hours (22
0r, p, m,) was cultured. The obtained culture solution was added to a fermentation medium 15 with the following composition in a 301 volume jar fermenter.
1 to 5 cm (volume), and stirred with aeration at 30°C (number of revolutions: 25 Or, p, m6, aeration i'15) 7
Culture was carried out using (m1n).
発酵培地組成;デキス) IJン509/l、大豆粕2
0 E/l、 KH2PO40,5!//1. Mg8
04・7H200,5&/A’、 0a00s 5
y/it、 p)(7,2(殺菌前)にN aOHで
調整する。Fermentation medium composition: dex) IJn 509/l, soybean meal 2
0 E/l, KH2PO40,5! //1. Mg8
04.7H200,5&/A', 0a00s 5
y/it, p) (7,2 (before sterilization) adjusted with NaOH.
培養中、培地のpHは制御しないで、72時間培養した
。培養液より菌体および沈殿物をPを
別し、沢液131を得た。Pi、、IA’の活性炭(和
光紬薬)に通塔して活性物質を吸着させ、水約3A!テ
水洗後、メタノールでさらに洗浄して不純物を除去する
。次にメタノール・ピリジン・アンモニアe水(86:
3 : 1 : 10 v/v)51を用いて吸着さ
れた物質を活性炭から溶出する。この溶出液を濃縮乾固
した後、少量の0.05 N NH,OH飽和酢酸エチ
ルに溶解する。この溶液を、予め同じ溶媒で懸濁したの
ちカラムに充填したシリカゲル(メルク社製)を用いて
クロマトグラフィーを行なう。活性画分を同じ方法で再
びクロマトグラフィーし、濃縮後、少量のトルエン・エ
タノール龜NH40H(45: 5: 0.1 v/v
)に溶解し、予め同じ溶媒で懸濁後カラムに充填したシ
リカゲルを用いてクロマトグラフィーを行なった。活性
画分を集めて濃縮後、酢酸エチルを加えてDO−81の
粉末を得た。この粉末を減圧下40℃で乾燥してDO−
81の剃(8約2001n9を得ることができた。During the culture, the pH of the medium was not controlled, and the culture was continued for 72 hours. The bacterial cells and precipitate were separated from the P from the culture solution to obtain a slurry 131. Pi, IA' activated carbon (Wako Tsumugi Pharmaceutical Co., Ltd.) is passed through the tower to adsorb the active substance, and the water is approximately 3A! After washing with water, the sample is further washed with methanol to remove impurities. Next, methanol, pyridine, ammonia e water (86:
The adsorbed substances are eluted from the activated carbon using 3:1:10 v/v) 51. The eluate is concentrated to dryness and then dissolved in a small amount of ethyl acetate saturated with 0.05 N NH,OH. This solution is suspended in the same solvent in advance, and then chromatography is performed using silica gel (manufactured by Merck & Co., Ltd.) packed in a column. The active fraction was chromatographed again in the same manner and after concentration, a small amount of toluene-ethanol solution NH40H (45:5:0.1 v/v
), and after suspension in the same solvent, chromatography was performed using silica gel packed in a column. After collecting and concentrating the active fractions, ethyl acetate was added to obtain a powder of DO-81. This powder was dried at 40°C under reduced pressure to obtain DO-
I was able to get 81 shaves (approximately 8 2001n9).
このようにして得られたDO−81の理化学的性質、抗
菌活性、抗腫瘍活性は前記の通りであった。The physicochemical properties, antibacterial activity, and antitumor activity of DO-81 thus obtained were as described above.
なお、本物質は、いわゆる(1.4)ベンゾジアゼピン
糸化合物に属し、この系統の化合物について広く認めら
れているように0−11位に水せたはアルコール(メタ
ノールなど)が付加(7たものが容易に得られる。これ
らの構造は下記のように示すことができる。This substance belongs to the so-called (1.4) benzodiazepine compounds, and as it is widely accepted that compounds of this type have water or alcohol (methanol, etc.) added to the 0-11 positions (7. are easily obtained. Their structures can be shown as follows.
しかし、これらの物質は前記のように減圧下に乾燥する
ことによって容易にDo−81に変わる。However, these substances are easily converted to Do-81 by drying under reduced pressure as described above.
実施例2
実施例1において、発酵培地組成を次のものに代えて竹
なう以外は実施例1と同様に行ない、DC−81約12
0■を得た。Example 2 The same procedure as in Example 1 was carried out except that the fermentation medium composition was replaced with the following and bamboo was used.
I got 0■.
発酵培地組成:可溶性殿粉40 y/1.大豆粕粉末3
0I/llコーン・スチーブ・リカー51// l 、
K2HPO40,51/ 11. MgSO4’7H
200,5g/11. Kolo、3g/l、 0
a0033.011/l、 pH7,2(殺菌前)に
NaOHで調整した。Fermentation medium composition: soluble starch 40 y/1. Soybean meal powder 3
0I/ll Corn Steve Liquor 51//l,
K2HPO40,51/ 11. MgSO4'7H
200.5g/11. Kolo, 3g/l, 0
a0033.011/l, pH was adjusted to 7.2 (before sterilization) with NaOH.
第1図はDo−81の赤外部吸収スペクトルを示す。 第1頁の続き (7■発 明 者 浅野行蔵 町田市中町3−9−10 (C発 明 者 森本眞 沼津市御幸町13−9 (7■発 明 者 今井良二 三島市徳倉1014−9 (老発 明 者 藤本和久 静岡県駿東郡長泉町下土狩1188 FIG. 1 shows the infrared absorption spectrum of Do-81. Continuation of page 1 (7■ Originator Yukizo Asano 3-9-10 Nakamachi, Machida City (C author: Makoto Morimoto) 13-9 Miyukicho, Numazu City (7■ Presenter: Ryoji Imai 1014-9 Tokukura, Mishima City (Old founder Kazuhisa Fujimoto 1188 Shimotsukari, Nagaizumi-cho, Sunto-gun, Shizuoka Prefecture
Claims (3)
C−81゜(1) New compound D specified by the following planar structural formula
C-81゜
生産する能力を有する微生物を培地に培養し、DC−8
1を培養物中に蓄積させ、培養物からDC−81を採取
することを特徴とする特許請求の範囲第1項記載の化合
物DC−81の製造法。(2) A microorganism that belongs to the genus Streptomyces and has the ability to produce Do-81 is cultured in a medium, and DC-8
A method for producing compound DC-81 according to claim 1, which comprises accumulating DC-81 in a culture and collecting DC-81 from the culture.
ロティカスDO−81(微工研菌寄第6502号)であ
る特許請求の範囲第2項記載の製造法。(3) The production method according to claim 2, wherein the microorganism is Streptomyces roseis phleroticus DO-81 (Feikokenbokuyori No. 6502).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP6363082A JPS58180487A (en) | 1982-04-16 | 1982-04-16 | Antibiotic dc-81 and its preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP6363082A JPS58180487A (en) | 1982-04-16 | 1982-04-16 | Antibiotic dc-81 and its preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPS58180487A true JPS58180487A (en) | 1983-10-21 |
Family
ID=13234852
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP6363082A Pending JPS58180487A (en) | 1982-04-16 | 1982-04-16 | Antibiotic dc-81 and its preparation |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS58180487A (en) |
Cited By (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2586683A1 (en) * | 1985-08-29 | 1987-03-06 | Centre Nat Rech Scient | New neothramycin derivatives, process for their preparation and their application as medicaments |
| US6562806B1 (en) | 1998-08-27 | 2003-05-13 | Spirogen Limited | Pyrrolobenzodiazepines |
| US6608192B1 (en) | 1998-08-27 | 2003-08-19 | Spirogen Limited | Collections of compounds |
| WO2004043963A1 (en) | 2002-11-14 | 2004-05-27 | Spirogen Limited | Pyrrolobenzodiazepines |
| US6747144B1 (en) | 1998-08-27 | 2004-06-08 | Spirogen Limited | Collections of compounds |
| US6909006B1 (en) | 1999-08-27 | 2005-06-21 | Spirogen Limited | Cyclopropylindole derivatives |
| US7049311B1 (en) | 1998-08-27 | 2006-05-23 | Spirogen Limited | Pyrrolbenzodiazepines |
| JP2007070318A (en) * | 2005-09-09 | 2007-03-22 | Marine Biotechnol Inst Co Ltd | Compound having antitumor activity and method for producing the same |
| US7244724B2 (en) | 2003-10-22 | 2007-07-17 | United States Of America, Represented By The Secretary, Department Of Health And Human Services | Pyrrolobenzodiazepines |
| US7429658B2 (en) | 2003-09-11 | 2008-09-30 | Spirogen Limited | Synthesis of protected pyrrolobenzodiazepines |
| US7511032B2 (en) | 2003-10-22 | 2009-03-31 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Pyrrolobenzodiazepine derivatives, compositions comprising the same and methods related thereto |
| US7528126B2 (en) | 2004-03-09 | 2009-05-05 | Spirogen Limited | Pyrrolobenzodiazepines |
| US7557099B2 (en) | 2004-03-01 | 2009-07-07 | Spirogen Limited | Pyrrolobenzodiazepines as key intermediates in the synthesis of dimeric cytotoxic pyrrolobenzodiazepines |
| US7612062B2 (en) | 2005-04-21 | 2009-11-03 | Spirogen Limited | Pyrrolobenzodiazepines |
| WO2010043880A1 (en) | 2008-10-17 | 2010-04-22 | Spirogen Limited | Unsymmetrical pyrrolobenzodiazepine-dimers for treatment of proliferative diseases |
| US7741319B2 (en) | 2004-03-01 | 2010-06-22 | Spirogen Limited | 11-hydroxy-5h-pyrrolo[2,1-c][1,4] benzodiazepin-5-one derivatives as key intermediates for the preparation of c2 substituted pyrrolobenzodiazepines |
| WO2011130613A1 (en) | 2010-04-15 | 2011-10-20 | Seattle Genetics, Inc. | Targeted pyrrolobenzodiazapine conjugates |
| WO2011130616A1 (en) | 2010-04-15 | 2011-10-20 | Spirogen Limited | Pyrrolobenzodiazepines used to treat proliferative diseases |
| WO2011130598A1 (en) | 2010-04-15 | 2011-10-20 | Spirogen Limited | Pyrrolobenzodiazepines and conjugates thereof |
| WO2013041606A1 (en) | 2011-09-20 | 2013-03-28 | Spirogen Sàrl | Pyrrolobenzodiazepines as unsymmetrical dimeric pbd compounds for inclusion in targeted conjugates |
| WO2013053871A1 (en) | 2011-10-14 | 2013-04-18 | Spirogen Sàrl | Pyrrolobenzodiazepines |
| WO2013053873A1 (en) | 2011-10-14 | 2013-04-18 | Spirogen Sàrl | Pyrrolobenzodiazepines |
| WO2013055993A1 (en) | 2011-10-14 | 2013-04-18 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
| US8487092B2 (en) | 2008-10-17 | 2013-07-16 | Spirogen Developments Sarl | Pyrrolobenzodiazepines |
| US8501934B2 (en) | 2008-07-22 | 2013-08-06 | Spirogen Sarl | Pyrrolobenzodiazepines |
| WO2013164592A1 (en) | 2012-04-30 | 2013-11-07 | Ucl Business Plc | Pyrrolobenzodiazepines |
| WO2013177481A1 (en) | 2012-05-25 | 2013-11-28 | Immunogen, Inc. | Benzodiazepines and conjugates thereof |
| US8637664B2 (en) | 2005-10-05 | 2014-01-28 | Spirogen Sarl | Alkyl 4- [4- (5-oxo-2,3,5, 11a-tetrahydo-5H-pyrrolo [2, 1-c] [1,4] benzodiazepine-8-yloxy)-butyrylamino]-1H-pyrrole-2-carboxylate derivatives and related compounds for the treatment of a proliferative disease |
| WO2014057120A1 (en) | 2012-10-12 | 2014-04-17 | Adc Therapeutics Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
| WO2014057119A1 (en) | 2012-10-12 | 2014-04-17 | Adc Therapeutics Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
| WO2014057074A1 (en) | 2012-10-12 | 2014-04-17 | Spirogen Sàrl | Pyrrolobenzodiazepines and conjugates thereof |
| WO2014057117A1 (en) | 2012-10-12 | 2014-04-17 | Adc Therapeutics Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
| WO2014057073A1 (en) | 2012-10-12 | 2014-04-17 | Spirogen Sàrl | Pyrrolobenzodiazepines and conjugates thereof |
| WO2014057072A1 (en) | 2012-10-12 | 2014-04-17 | Spirogen Sàrl | Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation |
| WO2014057113A1 (en) | 2012-10-12 | 2014-04-17 | Adc Therapeutics Sarl | Pyrrolobenzodiazepine - anti-psma antibody conjugates |
| WO2014057122A1 (en) | 2012-10-12 | 2014-04-17 | Adc Therapeutics Sàrl | Pyrrolobenzodiazepine-anti-cd22 antibody conjugates |
| US8829184B2 (en) | 2010-04-15 | 2014-09-09 | Spirogen Sarl | Intermediates useful for the synthesis of pyrrolobenzodiazepines |
| WO2014140862A2 (en) | 2013-03-13 | 2014-09-18 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| WO2014140174A1 (en) | 2013-03-13 | 2014-09-18 | Spirogen Sàrl | Pyrrolobenzodiazepines and conjugates thereof |
| WO2014159981A2 (en) | 2013-03-13 | 2014-10-02 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| US9102704B2 (en) | 2011-10-14 | 2015-08-11 | Spirogen Sarl | Synthesis method and intermediates useful in the preparation of pyrrolobenzodiazepines |
| WO2016037644A1 (en) | 2014-09-10 | 2016-03-17 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| US9376440B2 (en) | 2012-04-30 | 2016-06-28 | Medimmune Limited | Pyrrolobenzodiazepines as antiproliferative agents |
| WO2016166304A1 (en) | 2015-04-15 | 2016-10-20 | Van Berkel Patricius Hendrikus Cornelis | Site-specific antibody-drug conjugates |
| WO2017083451A1 (en) | 2015-11-10 | 2017-05-18 | Medimmune, Llc | Binding molecules specific for asct2 and uses thereof |
| US9713647B2 (en) | 2011-10-14 | 2017-07-25 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
| EP3235820A1 (en) | 2014-09-17 | 2017-10-25 | Genentech, Inc. | Pyrrolobenzodiazepines and antibody disulfide conjugates thereof |
| US9950078B2 (en) | 2013-10-11 | 2018-04-24 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| US9956299B2 (en) | 2013-10-11 | 2018-05-01 | Medimmune Limited | Pyrrolobenzodiazepine—antibody conjugates |
| US9956298B2 (en) | 2013-10-11 | 2018-05-01 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| US9968687B2 (en) | 2013-02-22 | 2018-05-15 | Abbvie Stemcentrx Llc | Anti-DLL3 antibody drug conjugates |
| US10010624B2 (en) | 2013-10-11 | 2018-07-03 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| US10017580B2 (en) | 2014-04-15 | 2018-07-10 | ADC Therpeutics S.A. | Humanized anti-Tn-MUC1 antibodies and their conjugates |
| US10029018B2 (en) | 2013-10-11 | 2018-07-24 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| US10035853B2 (en) | 2013-08-28 | 2018-07-31 | Abbvie Stemcentrx Llc | Site-specific antibody conjugation methods and compositions |
| GB201820725D0 (en) | 2018-12-19 | 2019-01-30 | Adc Therapeutics Sarl | Pyrrolobenzodiazepine resistance |
| WO2019025983A1 (en) | 2017-08-01 | 2019-02-07 | Medimmune, Llc | Bcma monoclonal antibody-drug conjugate |
| WO2019034764A1 (en) | 2017-08-18 | 2019-02-21 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
| WO2019096788A1 (en) | 2017-11-14 | 2019-05-23 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
| US10308721B2 (en) | 2014-02-21 | 2019-06-04 | Abbvie Stemcentrx Llc | Anti-DLL3 antibodies and drug conjugates for use in melanoma |
| US10420777B2 (en) | 2014-09-12 | 2019-09-24 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| WO2019224340A1 (en) | 2018-05-25 | 2019-11-28 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
| US10544223B2 (en) | 2017-04-20 | 2020-01-28 | Adc Therapeutics Sa | Combination therapy with an anti-axl antibody-drug conjugate |
| WO2020079229A1 (en) | 2018-10-19 | 2020-04-23 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
| WO2020079239A1 (en) | 2018-10-19 | 2020-04-23 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
| WO2020127573A1 (en) | 2018-12-19 | 2020-06-25 | Adc Therapeutics Sa | Pyrrolobenzodiazepine resistance |
| US10736903B2 (en) | 2012-10-12 | 2020-08-11 | Medimmune Limited | Pyrrolobenzodiazepine-anti-PSMA antibody conjugates |
| US10780096B2 (en) | 2014-11-25 | 2020-09-22 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
| US10799595B2 (en) | 2016-10-14 | 2020-10-13 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
| WO2020245283A1 (en) | 2019-06-07 | 2020-12-10 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
| US11059893B2 (en) | 2015-04-15 | 2021-07-13 | Bergenbio Asa | Humanized anti-AXL antibodies |
| US11135303B2 (en) | 2011-10-14 | 2021-10-05 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| WO2021211984A1 (en) | 2020-04-16 | 2021-10-21 | Regeneron Pharmaceuticals, Inc. | Diels-alder conjugation methods |
| US11160872B2 (en) | 2017-02-08 | 2021-11-02 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
| EP3939616A1 (en) | 2017-02-08 | 2022-01-19 | ADC Therapeutics SA | Pyrrolobenzodiazepine-antibody conjugates |
| US11318211B2 (en) | 2017-06-14 | 2022-05-03 | Adc Therapeutics Sa | Dosage regimes for the administration of an anti-CD19 ADC |
| US11352324B2 (en) | 2018-03-01 | 2022-06-07 | Medimmune Limited | Methods |
| US11370801B2 (en) | 2017-04-18 | 2022-06-28 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
| WO2022218970A2 (en) | 2021-04-12 | 2022-10-20 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
| WO2022218973A2 (en) | 2021-04-12 | 2022-10-20 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
| US11524969B2 (en) | 2018-04-12 | 2022-12-13 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof as antitumour agents |
| US11612665B2 (en) | 2017-02-08 | 2023-03-28 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| US11702473B2 (en) | 2015-04-15 | 2023-07-18 | Medimmune Limited | Site-specific antibody-drug conjugates |
| WO2024213113A2 (en) | 2023-04-13 | 2024-10-17 | Beigene Switzerland Gmbh | Targeted pyrrolobenzodiazapine conjugates |
| US12209099B2 (en) | 2019-03-15 | 2025-01-28 | Medimmune Limited | Azetidobenzodiazepine dimers and conjugates comprising them for use in the treatment of cancer |
| WO2025032556A1 (en) | 2023-08-10 | 2025-02-13 | Beigene Switzerland Gmbh | Bioactive conjugates, preparation method and use thereof |
| WO2025032555A1 (en) | 2023-08-10 | 2025-02-13 | Beigene Switzerland Gmbh | Bioactive conjugates, preparation method and use thereof |
-
1982
- 1982-04-16 JP JP6363082A patent/JPS58180487A/en active Pending
Cited By (132)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2586683A1 (en) * | 1985-08-29 | 1987-03-06 | Centre Nat Rech Scient | New neothramycin derivatives, process for their preparation and their application as medicaments |
| US6562806B1 (en) | 1998-08-27 | 2003-05-13 | Spirogen Limited | Pyrrolobenzodiazepines |
| US6608192B1 (en) | 1998-08-27 | 2003-08-19 | Spirogen Limited | Collections of compounds |
| US6747144B1 (en) | 1998-08-27 | 2004-06-08 | Spirogen Limited | Collections of compounds |
| US7049311B1 (en) | 1998-08-27 | 2006-05-23 | Spirogen Limited | Pyrrolbenzodiazepines |
| US7067511B2 (en) | 1998-08-27 | 2006-06-27 | Spirogen Limited | Pyrrolobenzodiazepines |
| US7265105B2 (en) | 1998-08-27 | 2007-09-04 | Spirogen Limited | Pyrrolobenzodiazepines |
| US7704924B2 (en) | 1998-08-27 | 2010-04-27 | Spirogen Limited | Library of compounds comprising pyrrolobenzodiazepine moieties |
| US6909006B1 (en) | 1999-08-27 | 2005-06-21 | Spirogen Limited | Cyclopropylindole derivatives |
| US7407951B2 (en) | 2002-11-14 | 2008-08-05 | Spirogen Limited | Pyrrolobenzodiazepines |
| WO2004043963A1 (en) | 2002-11-14 | 2004-05-27 | Spirogen Limited | Pyrrolobenzodiazepines |
| US7429658B2 (en) | 2003-09-11 | 2008-09-30 | Spirogen Limited | Synthesis of protected pyrrolobenzodiazepines |
| US7244724B2 (en) | 2003-10-22 | 2007-07-17 | United States Of America, Represented By The Secretary, Department Of Health And Human Services | Pyrrolobenzodiazepines |
| US7511032B2 (en) | 2003-10-22 | 2009-03-31 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Pyrrolobenzodiazepine derivatives, compositions comprising the same and methods related thereto |
| US7834005B2 (en) | 2003-10-22 | 2010-11-16 | The United States Of America As Represented By The Department Of Health And Human Services | Pyrrolobenzodiazepine derivatives, compositions comprising the same and methods related thereto |
| US7741319B2 (en) | 2004-03-01 | 2010-06-22 | Spirogen Limited | 11-hydroxy-5h-pyrrolo[2,1-c][1,4] benzodiazepin-5-one derivatives as key intermediates for the preparation of c2 substituted pyrrolobenzodiazepines |
| US7557099B2 (en) | 2004-03-01 | 2009-07-07 | Spirogen Limited | Pyrrolobenzodiazepines as key intermediates in the synthesis of dimeric cytotoxic pyrrolobenzodiazepines |
| EP2270010A1 (en) | 2004-03-01 | 2011-01-05 | Spirogen Limited | 11-hydroxy-5h-pyrrolo[2,1-c][1,4]benzodiazepin-5-one derivatives as key intermediates for the preparation of c2 substituted pyrrolobenzodiazepins |
| US7528126B2 (en) | 2004-03-09 | 2009-05-05 | Spirogen Limited | Pyrrolobenzodiazepines |
| US8633185B2 (en) | 2005-04-21 | 2014-01-21 | Spirogen Sarl | Pyrrolobenzodiazepines |
| US7612062B2 (en) | 2005-04-21 | 2009-11-03 | Spirogen Limited | Pyrrolobenzodiazepines |
| JP2007070318A (en) * | 2005-09-09 | 2007-03-22 | Marine Biotechnol Inst Co Ltd | Compound having antitumor activity and method for producing the same |
| US8637664B2 (en) | 2005-10-05 | 2014-01-28 | Spirogen Sarl | Alkyl 4- [4- (5-oxo-2,3,5, 11a-tetrahydo-5H-pyrrolo [2, 1-c] [1,4] benzodiazepine-8-yloxy)-butyrylamino]-1H-pyrrole-2-carboxylate derivatives and related compounds for the treatment of a proliferative disease |
| US8501934B2 (en) | 2008-07-22 | 2013-08-06 | Spirogen Sarl | Pyrrolobenzodiazepines |
| US8592576B2 (en) | 2008-10-17 | 2013-11-26 | Spirogen Sarl | Unsymmetrical pyrrolobenzodiazepine-dimers for treatment of proliferative diseases |
| US8940733B2 (en) | 2008-10-17 | 2015-01-27 | Spirogen Sarl | Unsymmetrical pyrrolobenzodiazepine-dimers for treatment of proliferative diseases |
| WO2010043880A1 (en) | 2008-10-17 | 2010-04-22 | Spirogen Limited | Unsymmetrical pyrrolobenzodiazepine-dimers for treatment of proliferative diseases |
| US9624227B2 (en) | 2008-10-17 | 2017-04-18 | Medimmune Limited | Unsymmetrical pyrrolobenzodiazepine-dimers for treatment of proliferative diseases |
| US8487092B2 (en) | 2008-10-17 | 2013-07-16 | Spirogen Developments Sarl | Pyrrolobenzodiazepines |
| WO2011130613A1 (en) | 2010-04-15 | 2011-10-20 | Seattle Genetics, Inc. | Targeted pyrrolobenzodiazapine conjugates |
| US9242013B2 (en) | 2010-04-15 | 2016-01-26 | Seattle Genetics Inc. | Targeted pyrrolobenzodiazapine conjugates |
| EP2789622A1 (en) | 2010-04-15 | 2014-10-15 | Spirogen Sàrl | Pyrrolobenzodiazepines used to treat proliferative diseases |
| US9732084B2 (en) | 2010-04-15 | 2017-08-15 | Medimmune Limited | Pyrrolobenzodiazepines used to treat proliferative diseases |
| WO2011130598A1 (en) | 2010-04-15 | 2011-10-20 | Spirogen Limited | Pyrrolobenzodiazepines and conjugates thereof |
| WO2011130616A1 (en) | 2010-04-15 | 2011-10-20 | Spirogen Limited | Pyrrolobenzodiazepines used to treat proliferative diseases |
| EP4039280A1 (en) | 2010-04-15 | 2022-08-10 | Seagen Inc. | Targeted pyrrolobenzodiazepine conjugates |
| US8829184B2 (en) | 2010-04-15 | 2014-09-09 | Spirogen Sarl | Intermediates useful for the synthesis of pyrrolobenzodiazepines |
| US10561739B2 (en) | 2010-04-15 | 2020-02-18 | Seattle Genetics Inc. | Targeted pyrrolobenzodiazapine conjugates |
| WO2013041606A1 (en) | 2011-09-20 | 2013-03-28 | Spirogen Sàrl | Pyrrolobenzodiazepines as unsymmetrical dimeric pbd compounds for inclusion in targeted conjugates |
| WO2013053873A1 (en) | 2011-10-14 | 2013-04-18 | Spirogen Sàrl | Pyrrolobenzodiazepines |
| US9713647B2 (en) | 2011-10-14 | 2017-07-25 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
| EP3388435A1 (en) | 2011-10-14 | 2018-10-17 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
| EP3309162A1 (en) | 2011-10-14 | 2018-04-18 | Seattle Genetics, Inc. | Targeted conjugates of pyrrolobenzodiazepines |
| US10328084B2 (en) | 2011-10-14 | 2019-06-25 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
| US11135303B2 (en) | 2011-10-14 | 2021-10-05 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| WO2013053871A1 (en) | 2011-10-14 | 2013-04-18 | Spirogen Sàrl | Pyrrolobenzodiazepines |
| US10329352B2 (en) | 2011-10-14 | 2019-06-25 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
| US9707301B2 (en) | 2011-10-14 | 2017-07-18 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
| US9102704B2 (en) | 2011-10-14 | 2015-08-11 | Spirogen Sarl | Synthesis method and intermediates useful in the preparation of pyrrolobenzodiazepines |
| WO2013055993A1 (en) | 2011-10-14 | 2013-04-18 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
| US9321774B2 (en) | 2012-04-30 | 2016-04-26 | Medimmune Limited | Pyrrolobenzodiazepines |
| WO2013164592A1 (en) | 2012-04-30 | 2013-11-07 | Ucl Business Plc | Pyrrolobenzodiazepines |
| US9376440B2 (en) | 2012-04-30 | 2016-06-28 | Medimmune Limited | Pyrrolobenzodiazepines as antiproliferative agents |
| WO2013177481A1 (en) | 2012-05-25 | 2013-11-28 | Immunogen, Inc. | Benzodiazepines and conjugates thereof |
| US9931415B2 (en) | 2012-10-12 | 2018-04-03 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| US11771775B2 (en) | 2012-10-12 | 2023-10-03 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| WO2014057119A1 (en) | 2012-10-12 | 2014-04-17 | Adc Therapeutics Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
| EP2839860A1 (en) | 2012-10-12 | 2015-02-25 | Spirogen Sàrl | Pyrrolobenzodiazepines and conjugates thereof |
| US10799596B2 (en) | 2012-10-12 | 2020-10-13 | Adc Therapeutics S.A. | Pyrrolobenzodiazepine-antibody conjugates |
| US10780181B2 (en) | 2012-10-12 | 2020-09-22 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| US10751346B2 (en) | 2012-10-12 | 2020-08-25 | Medimmune Limited | Pyrrolobenzodiazepine—anti-PSMA antibody conjugates |
| US10736903B2 (en) | 2012-10-12 | 2020-08-11 | Medimmune Limited | Pyrrolobenzodiazepine-anti-PSMA antibody conjugates |
| US9745303B2 (en) | 2012-10-12 | 2017-08-29 | Medimmune Limited | Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation |
| US10722594B2 (en) | 2012-10-12 | 2020-07-28 | Adc Therapeutics S.A. | Pyrrolobenzodiazepine-anti-CD22 antibody conjugates |
| US9889207B2 (en) | 2012-10-12 | 2018-02-13 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| US9919056B2 (en) | 2012-10-12 | 2018-03-20 | Adc Therapeutics S.A. | Pyrrolobenzodiazepine-anti-CD22 antibody conjugates |
| WO2014057122A1 (en) | 2012-10-12 | 2014-04-17 | Adc Therapeutics Sàrl | Pyrrolobenzodiazepine-anti-cd22 antibody conjugates |
| US9931414B2 (en) | 2012-10-12 | 2018-04-03 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| WO2014057113A1 (en) | 2012-10-12 | 2014-04-17 | Adc Therapeutics Sarl | Pyrrolobenzodiazepine - anti-psma antibody conjugates |
| US10695433B2 (en) | 2012-10-12 | 2020-06-30 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| WO2014057120A1 (en) | 2012-10-12 | 2014-04-17 | Adc Therapeutics Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
| WO2014057074A1 (en) | 2012-10-12 | 2014-04-17 | Spirogen Sàrl | Pyrrolobenzodiazepines and conjugates thereof |
| US11690918B2 (en) | 2012-10-12 | 2023-07-04 | Medimmune Limited | Pyrrolobenzodiazepine-anti-CD22 antibody conjugates |
| US10335497B2 (en) | 2012-10-12 | 2019-07-02 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| WO2014057117A1 (en) | 2012-10-12 | 2014-04-17 | Adc Therapeutics Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
| WO2014057073A1 (en) | 2012-10-12 | 2014-04-17 | Spirogen Sàrl | Pyrrolobenzodiazepines and conjugates thereof |
| US11779650B2 (en) | 2012-10-12 | 2023-10-10 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| WO2014057072A1 (en) | 2012-10-12 | 2014-04-17 | Spirogen Sàrl | Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation |
| EP3556400A1 (en) | 2013-02-22 | 2019-10-23 | AbbVie Stemcentrx LLC | Method of making antidll3-antibody pbd conjugates |
| US9968687B2 (en) | 2013-02-22 | 2018-05-15 | Abbvie Stemcentrx Llc | Anti-DLL3 antibody drug conjugates |
| US10478509B2 (en) | 2013-02-22 | 2019-11-19 | Abbvie Stemcentrx Llc | Anti-DLL3 antibody drug conjugates for treating cancer |
| WO2014159981A2 (en) | 2013-03-13 | 2014-10-02 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| WO2014140174A1 (en) | 2013-03-13 | 2014-09-18 | Spirogen Sàrl | Pyrrolobenzodiazepines and conjugates thereof |
| WO2014140862A2 (en) | 2013-03-13 | 2014-09-18 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| US10035853B2 (en) | 2013-08-28 | 2018-07-31 | Abbvie Stemcentrx Llc | Site-specific antibody conjugation methods and compositions |
| US9956299B2 (en) | 2013-10-11 | 2018-05-01 | Medimmune Limited | Pyrrolobenzodiazepine—antibody conjugates |
| US10029018B2 (en) | 2013-10-11 | 2018-07-24 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| US9956298B2 (en) | 2013-10-11 | 2018-05-01 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| US10010624B2 (en) | 2013-10-11 | 2018-07-03 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| US9950078B2 (en) | 2013-10-11 | 2018-04-24 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| US10308721B2 (en) | 2014-02-21 | 2019-06-04 | Abbvie Stemcentrx Llc | Anti-DLL3 antibodies and drug conjugates for use in melanoma |
| US10017580B2 (en) | 2014-04-15 | 2018-07-10 | ADC Therpeutics S.A. | Humanized anti-Tn-MUC1 antibodies and their conjugates |
| WO2016037644A1 (en) | 2014-09-10 | 2016-03-17 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| US10188746B2 (en) | 2014-09-10 | 2019-01-29 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| US10420777B2 (en) | 2014-09-12 | 2019-09-24 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| EP3235820A1 (en) | 2014-09-17 | 2017-10-25 | Genentech, Inc. | Pyrrolobenzodiazepines and antibody disulfide conjugates thereof |
| US10780096B2 (en) | 2014-11-25 | 2020-09-22 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
| US11702473B2 (en) | 2015-04-15 | 2023-07-18 | Medimmune Limited | Site-specific antibody-drug conjugates |
| US11059893B2 (en) | 2015-04-15 | 2021-07-13 | Bergenbio Asa | Humanized anti-AXL antibodies |
| WO2016166304A1 (en) | 2015-04-15 | 2016-10-20 | Van Berkel Patricius Hendrikus Cornelis | Site-specific antibody-drug conjugates |
| EP3719039A1 (en) | 2015-11-10 | 2020-10-07 | Medimmune, LLC | Binding molecules specific for asct2 and uses thereof |
| WO2017083451A1 (en) | 2015-11-10 | 2017-05-18 | Medimmune, Llc | Binding molecules specific for asct2 and uses thereof |
| US10799595B2 (en) | 2016-10-14 | 2020-10-13 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
| US11384098B2 (en) | 2017-02-08 | 2022-07-12 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
| EP3939616A1 (en) | 2017-02-08 | 2022-01-19 | ADC Therapeutics SA | Pyrrolobenzodiazepine-antibody conjugates |
| US11813335B2 (en) | 2017-02-08 | 2023-11-14 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| US11612665B2 (en) | 2017-02-08 | 2023-03-28 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| US11160872B2 (en) | 2017-02-08 | 2021-11-02 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
| US11370801B2 (en) | 2017-04-18 | 2022-06-28 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
| US10544223B2 (en) | 2017-04-20 | 2020-01-28 | Adc Therapeutics Sa | Combination therapy with an anti-axl antibody-drug conjugate |
| US11318211B2 (en) | 2017-06-14 | 2022-05-03 | Adc Therapeutics Sa | Dosage regimes for the administration of an anti-CD19 ADC |
| US11938192B2 (en) | 2017-06-14 | 2024-03-26 | Medimmune Limited | Dosage regimes for the administration of an anti-CD19 ADC |
| WO2019025983A1 (en) | 2017-08-01 | 2019-02-07 | Medimmune, Llc | Bcma monoclonal antibody-drug conjugate |
| US11649250B2 (en) | 2017-08-18 | 2023-05-16 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
| WO2019034764A1 (en) | 2017-08-18 | 2019-02-21 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
| WO2019096788A1 (en) | 2017-11-14 | 2019-05-23 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
| US11352324B2 (en) | 2018-03-01 | 2022-06-07 | Medimmune Limited | Methods |
| US11524969B2 (en) | 2018-04-12 | 2022-12-13 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof as antitumour agents |
| WO2019224340A1 (en) | 2018-05-25 | 2019-11-28 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
| WO2020079239A1 (en) | 2018-10-19 | 2020-04-23 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
| WO2020079229A1 (en) | 2018-10-19 | 2020-04-23 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
| GB201820725D0 (en) | 2018-12-19 | 2019-01-30 | Adc Therapeutics Sarl | Pyrrolobenzodiazepine resistance |
| WO2020127573A1 (en) | 2018-12-19 | 2020-06-25 | Adc Therapeutics Sa | Pyrrolobenzodiazepine resistance |
| US12209099B2 (en) | 2019-03-15 | 2025-01-28 | Medimmune Limited | Azetidobenzodiazepine dimers and conjugates comprising them for use in the treatment of cancer |
| US11484606B2 (en) | 2019-06-07 | 2022-11-01 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
| WO2020245283A1 (en) | 2019-06-07 | 2020-12-10 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
| WO2021211984A1 (en) | 2020-04-16 | 2021-10-21 | Regeneron Pharmaceuticals, Inc. | Diels-alder conjugation methods |
| WO2022218973A2 (en) | 2021-04-12 | 2022-10-20 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
| WO2022218970A2 (en) | 2021-04-12 | 2022-10-20 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
| WO2024213113A2 (en) | 2023-04-13 | 2024-10-17 | Beigene Switzerland Gmbh | Targeted pyrrolobenzodiazapine conjugates |
| WO2025032556A1 (en) | 2023-08-10 | 2025-02-13 | Beigene Switzerland Gmbh | Bioactive conjugates, preparation method and use thereof |
| WO2025032555A1 (en) | 2023-08-10 | 2025-02-13 | Beigene Switzerland Gmbh | Bioactive conjugates, preparation method and use thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS58180487A (en) | Antibiotic dc-81 and its preparation | |
| JPH02177890A (en) | New substance dc113 and production thereof | |
| JPH0684377B2 (en) | Novel compounds DC-88A and DC-89A1 | |
| DK141761B (en) | Process for the preparation of antibiotics aclacinomycin A and / or B or salts or deoxyribonucleic acid complexes thereof. | |
| JPS63258585A (en) | Antibiotic a10255 composite and factors, process thereof, and bacteria and production | |
| JPS584720B2 (en) | Anticoccidial substance and method for producing the same | |
| SU999981A3 (en) | Process for producing antibiotic complex having antitumoral effect | |
| JPS61216692A (en) | Cl-1577-b4 compound and its production | |
| CA1207694A (en) | Anthracycline compounds, process for production thereof, and uses thereof | |
| JPS6040840B2 (en) | Microbiological production of antibiotics | |
| EP0235795B1 (en) | Antibiotic f-0769, process for its production, and its use as a growth accelerating and feed efficiency increasing agent and as an antitumour agent | |
| CA1050462A (en) | Antibiotic from streptomyces atcc21386 | |
| JPS6010720B2 (en) | Production method of antibiotic C-15003 P-4 | |
| US3657421A (en) | Antibiotic x-5108 for stimulating growth | |
| JP3107455B2 (en) | New antibiotic MI481-42F4-A and method for producing the same | |
| JPH01112988A (en) | Dc-107 and production thereof | |
| JP2592468B2 (en) | Benanomycins A and B, novel antibiotics and their production | |
| PL108605B1 (en) | Method of producing acantomycin | |
| JPS5849235B2 (en) | New antibiotic XK-99 and its manufacturing method | |
| US3853992A (en) | Antibiotic em-98 | |
| US3328248A (en) | Antibiotic product and process of producing same | |
| JPS59161396A (en) | Novel antibiotic substance spicamycin | |
| JPH06312997A (en) | KO-8119 substance and its production method | |
| JPH08208644A (en) | New antibiotic clemimycin and its production and use | |
| JPS62201900A (en) | Streptoglamine type novel antibiotic and its microbiologicalproduction |